Katja Rosenkranz
Directeur/Membre du Conseil chez Dualyx NV
Profil
Katja Rosenkranz is currently the Director at dualyx NV since 2020 and a Partner at V-Bio Ventures BV since 2016.
Previously, she worked as the Director-Executive Board at Clearstream Banking AG from 2009 to 2012.
She also held positions as Director at AgomAb Therapeutics NV and COO, CFO & Head-Administration at Advitos GmbH from 2009 to 2012.
Postes actifs de Katja Rosenkranz
| Sociétés | Poste | Début |
|---|---|---|
V-Bio Ventures BV
 V-Bio Ventures BV Investment ManagersFinance V-Bio Ventures BV is an Independent Venture Capital firm founded in 2015 by Christina Takke and Willem Broekaert. V-Bio Ventures BV is headquartered in Ghent. | Private Equity Investor | 01/01/2016 |
Dualyx NV
 Dualyx NV Miscellaneous Commercial ServicesCommercial Services Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven. | Directeur/Membre du Conseil | 31/05/2020 |
Anciens postes connus de Katja Rosenkranz
| Sociétés | Poste | Fin |
|---|---|---|
Clearstream Banking AG
 Clearstream Banking AG Regional BanksFinance Clearstream Banking AG engages in providing commercial banking services. Its services include settlement, custody, global securities, financing, investment fund, business and IT solutions and customer support. The company is headquartered in Eschborn, Germany. | Corporate Officer/Principal | 31/03/2012 |
AgomAb Therapeutics NV
 AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | Directeur/Membre du Conseil | - |
Advitos GmbH
 Advitos GmbH Medical SpecialtiesHealth Technology Advitos GmbH manufactures, develops, and markets liver support therapy devices. Its therapy device helps enhance the survival of patients with life-threatening liver diseases. The company was founded by Dr. Bernhard Kreyman in 2005 and is headquartered in Munich, Germany. | Directeur Financier/CFO | 14/06/2012 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Clearstream Banking AG
Clearstream Banking AG Regional BanksFinance Clearstream Banking AG engages in providing commercial banking services. Its services include settlement, custody, global securities, financing, investment fund, business and IT solutions and customer support. The company is headquartered in Eschborn, Germany. | Finance |
Advitos GmbH
Advitos GmbH Medical SpecialtiesHealth Technology Advitos GmbH manufactures, develops, and markets liver support therapy devices. Its therapy device helps enhance the survival of patients with life-threatening liver diseases. The company was founded by Dr. Bernhard Kreyman in 2005 and is headquartered in Munich, Germany. | Health Technology |
V-Bio Ventures BV
V-Bio Ventures BV Investment ManagersFinance V-Bio Ventures BV is an Independent Venture Capital firm founded in 2015 by Christina Takke and Willem Broekaert. V-Bio Ventures BV is headquartered in Ghent. | Finance |
AgomAb Therapeutics NV
AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | Commercial Services |
Dualyx NV
Dualyx NV Miscellaneous Commercial ServicesCommercial Services Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven. | Commercial Services |